Exhibit 99.1

FOR IMMEDIATE  RELEASE

BIOCLINICA REPORTS 14.9% GROWTH IN FIRST QUARTER SERVICE REVENUES

-Announces Record Backlog of $125.8 million-

— Conference Call Today at 11:00 A.M. EDT —

NEWTOWN, PA, May 9, 2012 — BioClinica®, Inc. (NASDAQ: BIOC), a leading global provider of clinical trial management solutions, today announced its financial results for the first quarter ended March 31, 2012.

Financial highlights for the quarter ended March 31, 2012 include:

·                  Service revenues increased 14.9% to $18.6 million as compared with $16.1 million for the same period 2011.

·                  GAAP operating income was $1.6 million as compared with $567,000 including a restructuring charge of $679,000 for the same period 2011.

·                  GAAP net income improved year-over-year to $994,000, or $0.06 per fully diluted share as compared with $351,000, or $0.02 per fully diluted share. First quarter 2011 results included a restructuring charge of $426,000 or $0.03 per share.

·                  Non-GAAP operating income increased 17.1% to $2.2 million as compared with $1.8 million for the same period 2011.

·                  Non-GAAP net income increased 17.8% to $1.4 million compared with $1.2 million; this equated to $0.08 per fully diluted share, as compared with $0.07 per fully diluted share in the same period 2011.

·                  Backlog increased to a record $125.8 million.

Mark L. Weinstein, President and Chief Executive Officer of BioClinica said, “Business continued to be solid across our eClinical and medical imaging offerings. This was another strong quarter of year-over-year growth in service revenue, and the 14.9% growth represents the strongest percentage year-over-year increase in more than two years.  The strong first quarter results reflect the increased adoption of our technologies by our customers who are benefitting from the economic and competitive advantages of BioClinica’s clinical trial solutions that are flexible, easy-to-use and integrate easily with other clinical processes and technology applications. We enjoyed another strong quarter of contract signings, with enterprise-wide and multi-product agreements important components of our success.  Our eClinical solutions were bolstered by agreements with several companies involved in large, late-stage trials, as well as by a steady stream of business from small and mid-tier pharmaceutical and biotech companies. Our medical imaging solutions showed strength as well, with significant opportunities in the CNS, musculoskeletal and oncology areas.”

-more-

“BioClinica’s strong relationship with Microsoft continues to be an advantage to us, as we enable our customers to leverage Microsoft SharePoint and Microsoft Office Suite investments to drive down cost and improve information accessibility and usability. Using the Microsoft platform enables us to develop and deploy new technologies in a cost-efficient and timely manner, ultimately resulting in economic benefits for our clients.  Our recently signed OnPoint CTMS agreements in both the U.S. and Europe, and the recent partnership agreements signed with NextDocs and Paragon Solutions, are just a few examples of how our Microsoft relationship has been an important component of our success,” he continued.

“Our medical imaging solutions are also benefitting from strategic partnerships,” he added.  “Our partnership with Mirada Medical enables us to offers clients the most sophisticated level of clinical analysis for oncology PET scan image processing, and extends the amount of support that we provide in oncology clinical trials.”

Mr. Weinstein concluded, “Our record backlog of $125.8 million bodes well for our continued revenue growth throughout the next several quarters. During the first quarter we experienced strong contract signings, and interest in our product suite continues to increase as we broaden our offerings.  We remain confident in our business model, and are reiterating our expectations for full-year 2012 service revenue to be in the range of $73 to $77 million, our full-year GAAP EPS to be in the range of $0.26 to $0.32 per fully diluted share, and our full-year non-GAAP EPS to be in the range of $0.36 to $0.42 per fully diluted share.”

Conference Call Information

Management of BioClinica, Inc. will host a conference today at 11:00 a.m. EDT.  Those who wish to participate in the conference call may telephone 877-869-3847 from the U.S.; international callers may telephone 201-689-8261, approximately 15 minutes before the call.  There will be a simultaneous webcast on www.bioclinica.com.  A digital replay will be available by telephone approximately two hours after the call’s completion for two weeks, and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for international callers, Acct # 360; Replay ID # 390721. The replay will also be on the website under the “Investors” section at www.bioclinica.com for two weeks.

Non-GAAP Financial Information

BioClinica is providing information on 2012 and 2011 non-GAAP income from operations, non-GAAP net income and non-GAAP diluted earnings per share that exclude certain items, as well as the related income tax effects, because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. The non-GAAP information excludes, certain of which are recurring in nature, the impact of stock-based compensation, amortization of intangible assets related to acquisitions, restructuring charges and merger and acquisition costs. We believe the non-GAAP information provides supplemental information useful to investors in comparing our results of operations on a consistent basis from period to period. Management uses these non-GAAP measures in assessing our core operating performance and evaluating our ongoing business operations. These measures are not in accordance with, or an alternative for, generally accepted accounting principles (GAAP) and may be different from non-GAAP measures used by other companies. Therefore, the information may not necessarily be comparable to that of other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.  Investors are encouraged to review the reconciliations of these non-GAAP financial measures to the comparable GAAP results, which are included below in this press release.

2

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com

Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995.  In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the Company’s ability to convert backlog into revenue as a result of many factors, including but not limited to, contract cancelations; the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control.  The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements.  The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

- FINANCIAL TABLES TO FOLLOW –

3

BIOCLINICA, INC. AND SUBSIDIARIES

Consolidated Statements of Income

(in thousands, except per share data)

(unaudited)

4

BIOCLINICA, INC. AND SUBSIDIARIES

GAAP to non-GAAP Reconciliation (1)

(in thousands, except per share data)

(unaudited)

(1) This table presents a reconciliation of GAAP to non-GAAP income from operations, net income and diluted earnings per share for the three months ended March 31, 2012 and 2011.  The non-GAAP information excludes the impact of stock-based compensation, amortization of intangible assets related to acquisitions, restructuring charges and merger and acquisition costs.

(2) The effective tax rate used for fiscal 2012 is 36.8%

5

BIOCLINICA, INC. AND SUBSIDIARIES

Consolidated Balance Sheets

(in thousands)

(unaudited)

(3) During the first quarter 2012, the company repurchased 100,700 shares of BioClinica stock at an average price of $5.05 per share, as part of its stock repurchase program.  At the end of the first quarter, there was $334,000 of funds remaining that may yet be used to repurchase shares under the plan that originally authorized purchases up to $2 million.

6

BIOCLINICA, INC. AND SUBSIDIARIES

Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

####

7